Patents Assigned to Institut Pasteur De Lille
-
Publication number: 20240238244Abstract: A compound of formula (I) or a pharmaceutically acceptable salt and/or hydrate thereof, for use in the treatment of a viral pulmonary disease or a chronic respiratory distress syndrome (CRDS) resulting from a viral pulmonary disease in a subject, the disease being different from COVID-19, wherein formula (I) is Z—R-A-R?—Y, including plerixafor.Type: ApplicationFiled: May 5, 2022Publication date: July 18, 2024Applicants: 4LIVING BIOTECH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DE LILLE, UNIVERSITE DE LILLE, CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALEInventors: Revital RATTENBACH, Keren BISMUTH, Jérome BRETON, François TROTTEIN, Valentin SENCIO
-
Patent number: 11926664Abstract: Monocytopoiesis is a hematological process that supplies the periphery with monocytes and subsequently with macrophages and monocyte-derived dendritic cells. Typically, monocytes circulate in the bloodstream for a very short time before undergoing apoptosis, however, stimulatory signals can trigger monocyte survival by inhibiting the apoptotic pathway, and thus contribute to the maintenance of the inflammatory response. Accordingly, there is a need for methods and pharmaceutical compositions for modulating monocytopoiesis. Now, the inventors show that type I interferons signaling promote the differentiation of monocyte-derived phagocytes at the level of their progenitors. Importantly, IFN-alpha and -beta were found to efficiently generate the development of monocyte-derived antigen-presenting cells while having no impact on the precursor activity of conventional dendritic cells. Accordingly, modulators of type I interferon (e.g.Type: GrantFiled: July 24, 2018Date of Patent: March 12, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE LILLEInventors: Lionel Poulin, Corentin Lasseaux, Mathias Chamaillard
-
Publication number: 20230157994Abstract: A method of treating COVID-19 in a patient. The patient may be in moderate to advanced stages of COVID-19 infection. The method includes administering to the patient a therapeutically effective amount of at least one antagonist or inhibitor of chemokine receptor CXCR4. The at least one antagonist or inhibitor of chemokine receptor CXCR4 is distinct from hydroxychloroquine.Type: ApplicationFiled: May 5, 2021Publication date: May 25, 2023Applicants: 4LIVING BIOTECH, UNIVERSITE DE BORDEAUX, CENTRE HOSPITALIER DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM, INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE LILLEInventors: Patrick BERGER, Isabelle DUPIN, Renaud PREVEL, Chloé JAMES, Pierre-Olivier GIRODET, Keren BISMUTH, Revital RATTENBACH, Jérôme BRETON, Francois TROTTEIN, Valentin SENCIO
-
Patent number: 11446372Abstract: A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinical B. pertussis isolates was developed. The fim3 expression in BPZE1f3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.Type: GrantFiled: April 14, 2020Date of Patent: September 20, 2022Assignees: Institut Pasteur de Lille, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)Inventors: Anne-Sophie Debrie, Dominique Raze, Camille Locht
-
Patent number: 11364219Abstract: The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of several chronic diseases. Thus characterization of new post-biotic compounds inducing beneficial changes on host-microbiota interactions may be highly desirable. The inventors showed that Nlrp6 diurnally coordinates cyclical adaptation of the gut microbiota diversity to epithelial plasticity in response to a treatment with a Csnk2 inhibitor. The invention therefore relates to an inhibitor of Csnk2, for use in the treatment of microbiome dysregulations notably associated with circadian clock disruption. Said inhibitor may be selected among chemically synthesized or natural selective Csnk2 inhibitors such as flavones.Type: GrantFiled: May 19, 2017Date of Patent: June 21, 2022Assignees: INSERM (INSTITUT NATION DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LILLE, INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CRNS—Inventor: Mathias Chamaillard
-
Methods and kits for diagnosing postoperative pulmonary infections in patients who underwent surgery
Patent number: 11226343Abstract: The present invention relates to methods and kits for diagnosing a postoperative pulmonary infection in a patient who underwent surgery. More particularly, the present invention relates to a method for diagnosing a postoperative pulmonary infection in a patient who underwent surgery, comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said patient, at a time point comprised between 3 h and 30 h after surgery.Type: GrantFiled: April 7, 2017Date of Patent: January 18, 2022Assignees: BIOTHELIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LE RECHERCHE MEDICAL), INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, UNIVERSITE DE LILLEInventors: Philippe Lasalle, Sidney Chocron, Nathalie De Freitas Caires -
Patent number: 10875896Abstract: Hepatitis E virus (HEV) is responsible for over 50% of acute viral hepatitis cases worldwide. The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and are the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i and ORF2g proteins are thus the subject matter of the present invention as well as antibodies specific for the proteins and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection.Type: GrantFiled: January 29, 2018Date of Patent: December 29, 2020Assignees: INSERM (Institut National de la Santé´et de la Recherche Médicale), Institut Pasteur de Lille, Centre National de la Recherche Scientifique (CNRS), Universitë{umlaut over ( )}de Lille, Centre Hospitalier Regional Universitaire de LilleInventors: Laurence Cocquerel-Deproy, Claire Montpellier, Jean Dubuisson, Anne Goffard
-
Patent number: 10736937Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza. In particular, the present invention relates to a method of treating a bacterial superinfection post-influenza in a subject in need thereof comprising administering the subject with a therapeutically effective amount of a flagellin polypeptide optionally in combination with at least one antibiotic.Type: GrantFiled: December 22, 2015Date of Patent: August 11, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE LILLE, INSTITUT PASTEUR DE LILLEInventors: Jean-Claude Sirard, Christophe Carnoy, François Trottein, Rémi Porte
-
Patent number: 10682377Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.Type: GrantFiled: March 29, 2017Date of Patent: June 16, 2020Assignees: Institut Pasteur de Lille, INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALEInventors: Luis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
-
Patent number: 10584383Abstract: The present invention relates to a method for predicting mortality of a test patient with chronic heart failure comprising based on detecting the expression level of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 8. The present invention also relates to a method for predicting cardiac remodeling after myocardial infarction in a test patient based on detecting the expression level of one or more lncRNAs selected from SEQ ID NOs 1 to 8.Type: GrantFiled: March 18, 2015Date of Patent: March 10, 2020Assignees: MEDIZINISCHE HOCHSCHULE HANNOVER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITÉ DE LILLE 2 (LILLE 2)—UNIVERSITY OF LAW AND HEALTH, CENTRE HOSPITALIER UNIVERSITAIRE LILLE (CHU), INSTITUT PASTEUR DE LILLE (IPL)Inventors: Thomas Thum, Regalla Kumarswamy, Florence Pinet, Christophe Bauters, Pascal De Groote
-
Patent number: 10435450Abstract: Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.Type: GrantFiled: January 21, 2016Date of Patent: October 8, 2019Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DE LILLE, UNIVERSITA' DEGLI STUDI DI PAVIA, UNIVERSITÉ DE LILLEInventors: Jerome Vicogne, Oleg Melnyk, Nathalie Ollivier, Eric Adriaenssens, Berenice Leclercq, Claire Simonneau, Giovanni De Nola, Ermanno Gherardi, Hugo De Jonge
-
Patent number: 10426816Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.Type: GrantFiled: February 20, 2014Date of Patent: October 1, 2019Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Pasteur de LilleInventors: Jean-Claude Sirard, Jose A. Chabalgoity
-
Patent number: 10420827Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.Type: GrantFiled: November 1, 2017Date of Patent: September 24, 2019Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de Lille, National University of Ireland MaynoothInventors: Camille Locht, Bernard Mahon, Heather Kavanaugh
-
Patent number: 10369207Abstract: A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.Type: GrantFiled: July 12, 2018Date of Patent: August 6, 2019Assignees: National University of Singapore, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de LilleInventors: Sylvie Claudette Alonso, Annabelle Rui Fen Lim, Camille Locht
-
Patent number: 10323016Abstract: The present invention is directed to novel compounds of formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.Type: GrantFiled: June 11, 2015Date of Patent: June 18, 2019Assignees: UNIVERSITE DE LILLE 2 DROIT ET SANTE, INSTITUT PASTEUR DE LILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Julie Charton, Benoit Deprez, Florence Leroux, Bart Staels, Anne Muhr-Tailleux, Nathalie Hennuyer, Sophie Lestavel, Manuel Lassalle, Barbara Dubanchet
-
Patent number: 10287326Abstract: Disclosed is a polypeptide including or consisting of the amino acid sequence SEQ id no:1, for use in the treatment or prevention of an inflammatory disease. It further encompasses a nucleic acid sequence encoding a polypeptide, a vector including a nucleic acid and a host cell including a nucleic acid sequence and/or a vector, for use in the treatment or prevention of an inflammatory disease. Also disclosed is a pharmaceutical composition or a food composition including a polypeptide, a nucleic acid sequence, a vector or a host cell and a pharmaceutically acceptable carrier or a dairy product, for the treatment of inflammatory disease. Additionally, a method for the screening of bacteria having immunomodulatory properties is disclosed.Type: GrantFiled: July 7, 2015Date of Patent: May 14, 2019Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), INSTITUT PASTEUR DE LILLE (IPL)Inventors: Gwenael Jan, Benoit Foligne, Helene Falentin, Stephanie-Marie Deutsch
-
Patent number: 10265302Abstract: The present invention relates to the compound of formula (I) for use in the treatment of a nonsense-mutation-mediated genetic disease.Type: GrantFiled: January 29, 2018Date of Patent: April 23, 2019Assignees: UNIVERSITE DE LILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR DE LILLEInventors: Fabrice Lejeune, Benoit Deprez, Terence Beghyn, Sara Sofia Gonzalez-Hilarion
-
Patent number: 10046044Abstract: A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.Type: GrantFiled: April 3, 2017Date of Patent: August 14, 2018Assignees: National University of Singapore, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de LilleInventors: Sylvie Claudette Alonso, Rui Fen Annabelle Lim, Camille Locht
-
Patent number: 9956284Abstract: The present invention relates to novel peptide compounds derived from flagellin originating from Salmonelle enterica that exhibit an in vivo immune adjuvant activity.Type: GrantFiled: October 7, 2016Date of Patent: May 1, 2018Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, INSTITUT PASTEUR DE LILLEInventor: Jean-Claude Sirard
-
Patent number: 9932309Abstract: The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.Type: GrantFiled: July 28, 2015Date of Patent: April 3, 2018Assignees: Universite de Lille 2 Droit et Sante, Institut Pasteur de Lille, INSERMInventors: Julie Charton, Benoit Deprez, Florence Leroux, Bart Staels, Anne Muhr-Tailleux, Nathalie Hennuyer, Sophie Lestavel, Sylvain Picon, Karen Aknin, Rajaa Boulahjar, Barbara Dubanchet